These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 25665673)
1. Survival Outcome Between Hepatic Resection and Transarterial Embolization for Hepatocellular Carcinoma More Than 10 cm: A Propensity Score Model. Chan YC; Kabiling CS; Pillai VG; Aguilar G; Wang CC; Chen CL World J Surg; 2015 Jun; 39(6):1510-8. PubMed ID: 25665673 [TBL] [Abstract][Full Text] [Related]
2. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis . Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070 [TBL] [Abstract][Full Text] [Related]
3. Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. Liu PH; Hsia CY; Lee YH; Hsu CY; Huang YH; Su CW; Lee RC; Lin HC; Huo TI J Surg Oncol; 2015 Mar; 111(4):404-9. PubMed ID: 25643842 [TBL] [Abstract][Full Text] [Related]
4. Combined resection and radiofrequency ablation versus transarterial embolization for intermediate-stage hepatocellular carcinoma: A propensity score matching study. Espinosa W; Liu YW; Wang CC; Lin CC; Wang JH; Lu SN; Hung CH J Formos Med Assoc; 2018 Mar; 117(3):197-203. PubMed ID: 28411877 [TBL] [Abstract][Full Text] [Related]
5. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis. Guo Z; Zhong JH; Jiang JH; Zhang J; Xiang BD; Li LQ Ann Surg Oncol; 2014 Sep; 21(9):3069-76. PubMed ID: 24728740 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354 [TBL] [Abstract][Full Text] [Related]
7. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F; Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853 [TBL] [Abstract][Full Text] [Related]
8. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. Pecorelli A; Lenzi B; Gramenzi A; Garuti F; Farinati F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Cabibbo G; Felder M; Morisco F; Gasbarrini A; Baroni GS; Foschi FG; Biasini E; Masotto A; Virdone R; Bernardi M; Trevisani F; Liver Int; 2017 Mar; 37(3):423-433. PubMed ID: 27566596 [TBL] [Abstract][Full Text] [Related]
9. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching. Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976 [TBL] [Abstract][Full Text] [Related]
10. Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching. Kaplan DE; Mehta R; D'Addeo K; Gade TP; Taddei TH J Vasc Interv Radiol; 2018 Apr; 29(4):540-549.e4. PubMed ID: 29477619 [TBL] [Abstract][Full Text] [Related]
11. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767 [TBL] [Abstract][Full Text] [Related]
12. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Zhong JH; Ke Y; Gong WF; Xiang BD; Ma L; Ye XP; Peng T; Xie GS; Li LQ Ann Surg; 2014 Aug; 260(2):329-40. PubMed ID: 24096763 [TBL] [Abstract][Full Text] [Related]
13. Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage A after liver resection or transarterial chemoembolization: a propensity score analysis. Zhu SL; Ke Y; Peng YC; Ma L; Li H; Li LQ; Zhong JH PLoS One; 2014; 9(12):e115834. PubMed ID: 25541684 [TBL] [Abstract][Full Text] [Related]
14. [Comparison liver resection with transarterial chemoembolization for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma patients on long-term survival after SPSS propensity score matching]. Ke Y; Zhong J; Guo Z; Liang Y; Li L; Xiang B Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(10):747-50. PubMed ID: 24844957 [TBL] [Abstract][Full Text] [Related]
15. Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment. Jun CH; Yoon JH; Cho E; Shin SS; Cho SB; Kim HJ; Park CH; Kim HS; Choi SK; Rew JS Medicine (Baltimore); 2017 Apr; 96(17):e6745. PubMed ID: 28445298 [TBL] [Abstract][Full Text] [Related]
16. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study. Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C J BUON; 2017; 22(1):150-156. PubMed ID: 28365948 [TBL] [Abstract][Full Text] [Related]
17. Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. Kim H; Ahn SW; Hong SK; Yoon KC; Kim HS; Choi YR; Lee HW; Yi NJ; Lee KW; Suh KS; Br J Surg; 2017 Jul; 104(8):1045-1052. PubMed ID: 28480964 [TBL] [Abstract][Full Text] [Related]
18. Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization. Ciria R; López-Cillero P; Gallardo AB; Cabrera J; Pleguezuelo M; Ayllón MD; Luque A; Zurera L; Espejo JJ; Rodríguez-Perálvarez M; Montero JL; de la Mata M; Briceño J Eur J Surg Oncol; 2015 Sep; 41(9):1153-61. PubMed ID: 26118317 [TBL] [Abstract][Full Text] [Related]
19. Treatment of hepatocellular carcinoma: beyond international guidelines. Sangiovanni A; Colombo M Liver Int; 2016 Jan; 36 Suppl 1():124-9. PubMed ID: 26725909 [TBL] [Abstract][Full Text] [Related]
20. Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era. Waziry R; Gomaa A; Waked I; Dore GJ Arab J Gastroenterol; 2018 Mar; 19(1):26-32. PubMed ID: 29506913 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]